



PREFERRED SPECIALTY MANAGEMENT POLICY

- POLICY:** Pulmonary Arterial Hypertension and Related Lung Disease – Inhaled Prostacyclin Products Preferred Specialty Management Policy
- Tyvaso® (treprostinil inhalation solution – United Therapeutics)
 - Tyvaso DPI™ (treprostinil inhalation powder – United Therapeutics/Mannkind)
 - Ventavis® (iloprost inhalation solution – Actelion/Janssen)

REVIEW DATE: 10/11/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Tyvaso, Tyvaso DPI, and Ventavis are inhaled prostacyclin vasodilators (prostacyclin mimetics) indicated for the treatment of:¹⁻³

- **Pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1.** Tyvaso and Tyvaso DPI are specifically indicated to improve exercise ability whereas Ventavis is indicated to improve a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration.

Tyvaso and Tyvaso DPI are also indicated for:¹

- **Pulmonary hypertension associated with interstitial lung disease (WHO Group 3).** Tyvaso and Tyvaso DPI are indicated to improve exercise ability for this population.

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of the Preferred Product(s). For all Medications (Preferred and Non-Preferred), the patient is required to meet the respective Prior Authorization Policy criteria. The program also directs the patient to try one Preferred Product prior to the approval of a Non-Preferred Product. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals are provided for 1 year in duration. If the patient meets the standard *Pulmonary Arterial Hypertension and Related Lung Disease – Inhaled Prostacyclin Products Prior Authorization Policy* criteria but has not tried the Preferred Product, approval for the Preferred Product(s) will be authorized.

Preferred Product: Tyvaso, Tyvaso DPI

Non-Preferred Product: Ventavis

Pulmonary Arterial Hypertension and Related Lung Disease – Inhaled Prostacyclin non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.

NON-PREFERRED PRODUCT EXCEPTION CRITERIA

Non-Preferred Product	Exception Criteria
Ventavis	<ol style="list-style-type: none">1. Approve for 1 year if the patient meets both of the following (A and B):<ol style="list-style-type: none">A) Patient meets the standard <i>Pulmonary Arterial Hypertension – Inhaled Prostacyclin Products Prior Authorization Policy</i> criteria; ANDB) Patient meets one of the following (i, ii, or iii):<ol style="list-style-type: none">i. Patient has been established on Ventavis; ORii. Patient has tried Tyvaso or Tyvaso DPI; ORiii. Patient already has the device for Ventavis.2. For a patient who meets the standard <i>Pulmonary Arterial Hypertension and Related Lung Disease – Inhaled Prostacyclin Products Prior Authorization Policy</i> criteria but does not meet 1B, approve the Preferred Product.

REFERENCES

1. Tyvaso® inhalation solution [prescribing information]. Research Triangle Park, NC: United Therapeutics; May 2022.
2. Ventavis® inhalation solution [prescribing information]. Titusville, NJ: Actelion/Janssen; March 2022.
3. Tyvaso DPI™ oral inhalation powder [prescribing information]. Danbury, CT and Research Triangle Park, NC: MannKind and United Therapeutics; May 2022.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes. Name of the Policy updated to add "and Related Lung Disease" to the header.	10/12/2022
Selected Revision	Tyvaso DPI was added as a Preferred Product. Criteria were altered for the Non-Preferred Product (Ventavis [iloprost inhalation solution]) to provide an exception for use if the patient has tried Tyvaso DPI.	11/30/2022
Annual Revision	No criteria changes.	10/11/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna